LlewCD
@LlewCD
Followers
190
Following
1K
Statuses
1K
Lead Pharmacist for Myeloid Neoplasms at Guys and St Thomas’ NHS Foundation Trust
London
Joined January 2011
RT @MPN_Hub: CONGRESS #ASH24 | PRESENTATION John Mascarenhas, @IcahnMountSinai discussed results from the phase III BOREAS study. Navtemadl…
0
7
0
@RenoHemonc @BrJHaem @jm_osullivan @beth_psaila Pacritinib is currently commercially unavailable in the UK but is commented on in the paper regarding where it may fit in the greater schema
0
0
0
A lovely review of JAKi and when to use from @beth_psaila and @jm_osullivan the landscape is moving quickly and this is fantastic summary of clinicians can utilise the options
In a Nutshell: When, which and how to switch: Navigating JAK inhibitors in myelofibrosis @jm_osullivan @beth_psaila
1
0
4
RT @GonzaloBentoli1: Improving the outcome in MF. A lot to investigate 🔬 and have real life data, especially in GvHD prophylaxis. Chair: @D…
0
1
0
RT @AlexBickMDPhD: 🩸New research in @BloodJournal led by @beckyzon reveals that JAK2-mutant #CHIP significantly increases the risk of venou…
0
3
0
RT @AaronGoodman33: Tumors Secrete Erythropoietin EPO⬆️ HCC RCC Hemangioblastoma Uterine leiomyomata Pheochromocytoma Differentiate fr…
0
62
0
RT @Kiruthikah_T: Our new podcast for anyone affected by pancreatic cancer is out, the first couple of episodes focus on what to expect fro…
0
3
0
RT @AaronGoodman33: Menin Inhibitors! Will do podcast soon on FDA approval, study, and clinical use New class of drugs approved for relap…
0
45
0
RT @BloodJournal: JAK2-mutant CHIP confers a greater risk of VTE than heterozygous thrombophilia but is present at a lower frequency in the…
0
22
0
RT @JAMA_current: Polycythemia vera is a clonal myeloproliferative neoplasm that causes erythrocytosis and is typically associated with a J…
0
19
0
Really exciting detail about the role of IVIg in BSAb and how the cadence of dosing can influence infections . #ASH24
#ASH24 Effects of IVIG on Infections in Recipients of Teclistamab for MM. IVIG within the past 30 days may lower the risk of high-grade and bacterial infections #mmsm #bmtsm @hcheruvalath @MeeraMohanMD
0
0
0
Interesting expansion of immunotherapy to the Myelodysplastic arena. . The questions of immunotherapy toxicity become ever more prevalent in healthcare and how we identify and manage them in routine practice
👉👉👉Our brand new paper 🚨 led by Dr Ian Bouligny & @garciamanero A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms | @LeukemiaJnl
0
0
0
RT @NicoGagelmann: 🎉Finally out🎉 Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis @AjHematology 👉usi…
0
21
0
RT @Kiruthikah_T: Our podcast is out! latest oncology updates for health care professionals - all you need to know about different topics…
0
1
0
RT @PriyaSriRajah: Also be aware of new QR4 which outperforms QRISK3 in assessing risk of cardiovascular disease published by Hippisley-Cox…
0
1
0
RT @tomleblancMD: Big news today for the #leukemia community, especially for our patients in need! #Revumenib was approved today by @US_FDA…
0
6
0